Defunct Company
Total Trials
15
As Lead Sponsor
14
As Collaborator
1
Total Enrollment
2,485
NCT00004408
Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease
Phase: Phase 3
Role: Lead Sponsor
Start: Nov 30, 1997
Completion: Nov 30, 1999
NCT00081627
Clinical Trial in Patients With Metastatic Colorectal Cancer
Phase: Phase 2
Start: Apr 30, 2004
Completion: Jan 31, 2007
NCT00235898
Start: May 31, 2005
Completion: Not specified
NCT00434369
5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Treating Advanced Breast Cancer Patients
Start: Feb 28, 2006
NCT00337389
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.
Start: May 31, 2006
NCT00432562
A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.
Phase: Phase 1
Start: Feb 28, 2007
Completion: Dec 31, 2007
NCT00663481
A Clinical Trial of CoFactor Formulations and Leucovorin Administered Intravenously in Healthy, Adult Subjects.
Start: Apr 30, 2008
Completion: May 31, 2008
NCT00664170
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Completion: Apr 30, 2009
NCT01790087
ANX-188 Thorough QT/QTc Study in Healthy Volunteers
Start: Feb 28, 2013
Completion: Jun 30, 2013
NCT01737814
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
Start: May 31, 2013
NCT02093468
Evaluation of MST-188 in Acute Lower Limb Ischemia
Start: Jun 30, 2014
NCT02449616
Evaluation of Repeat Administration of Purified Poloxamer 188
Start: Jun 30, 2015
NCT02596477
Evaluation of Vepoloxamer in Chronic Heart Failure
Start: Oct 31, 2015
NCT02646358
Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer
Start: Jan 31, 2016
NCT02694393
Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis
Phase: Phase 1/2
Role: Collaborator
Start: Feb 29, 2016
Completion: Jul 21, 2022